The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway.
 
Razelle Kurzrock
Leadership - CureMatch
Stock and Other Ownership Interests - Actuate Therapeutics; CureMatch
Honoraria - AACR; AACR; Actuate Therapeutics; Casdin Capital; Casdin Capital; Casdin Capital; Casdin Capital; Cedars-Sinai; Frankel Group; Global Biomarkers Consortium; Health Advances; Janssen; Jubilant Biosys; Kaiser Permanente; Mayo Clinic Cancer Center; NCCN; Northwestern University; NXT Health Strategies; NXT Health Strategies; Pancreatic Cancer Action Network; Segal Cancer Center; Seminars in Oncology; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sylvester Cancer Center; Sylvester Cancer Center; The Dedham Group; UCSD Genomics Program Talk; XBiotech; XBiotech; Yale Cancer Center
Consulting or Advisory Role - AACR; Actuate Therapeutics; CTRC-EAB San Antonio; Janssen; Jubilant Biosys; Merck; SAIC NCI CCCT IDSE; Sequenom; XBiotech
Research Funding - Centocor Ortho Biotech; EMD Serono; EMD Serono; EMD Serono; Exelixis; Foundation Medicine; Genentech Mypath; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; Merck; Merck; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sequenom; XBiotech
Patents, Royalties, Other Intellectual Property - Patent; Patent; Patent; Patent
Travel, Accommodations, Expenses - AACR; AACR; ASCPT; Association of American Cancer Institutes; Caris Centers of Excellence; Caris Centers of Excellence; Cedars-Sinai; CureMatch; EMD Serono; EMD Serono & Quintiles; EMD Serono & Quintiles; FDA-OCRA; Gateway Research Advisory Committee; Gateway Research Advisory Committee; Genentech; Global Biomarkers Consortium; Global Source Ventures/Novena Therapeutics; Guardant Health; Guardant Health; ICRP; Journal of Precision Medicine; Kaiser Permanente; Lynx Group; Mayo Clinic Cancer Center; MedImmune/JK Associates Medical Communications Group; Meyer; Orbimed/Global Source Ventures; Pancreatic Cancer Action Network; Sylvester Cancer Center; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Clearlight Diagnostics; Genentech; Inflection Biosciences; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem; Zymeworks
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; OncoMed; TRACON Pharma
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); NCI (Inst); Novartis (Inst); Regeneron (Inst); TRACON Pharma (Inst)
 
John D. Hainsworth
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Celgene (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Novartis (Inst)
 
David R. Spigel
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
 
Ron Bose
Honoraria - Genentech; Novartis
Consulting or Advisory Role - Genentech
 
Charles Swanton
Stock and Other Ownership Interests - Epic Sciences
Honoraria - Boehringer Ingelheim; GlaxoSmithKline; Novartis
Consulting or Advisory Role - Sarah Cannon Research Institute
Research Funding - Boehringer Ingelheim
 
Howard A. Burris
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen Biotech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Bongin Yoo
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Mary Stanley Beattie
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
Rajesh Patel
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Katja Schulze
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Elaine Tat Lam
Research Funding - Genentech/Roche